进展期胃癌新辅助化疗前后IL-6、IL-10的变化及其临床意义

目的 观察进展期胃癌患者新辅助化疗前后白细胞介素6(IL-6)、白细胞介素10(IL-10)水平的变化,寻求新辅助化疗有效性的新的参考指标.方法 通过ELISA方法对51例进展期胃癌患者行新辅助化疗前后的IL-6、IL-10水平进行检测,分析IL-6、IL-10水平的变化与新辅助化疗有效性是否相关.根据新辅助化疗是否有效将患者分为A组(有效组:完全缓解+部分缓解),B组(无效组:疾病稳定+疾病进展).随后应用免疫组化方法,检测IL-6在新辅助化疗前后胃癌组织中的表达情况.结果 A组患者IL-6水平显著下降(P<0.05),IL-10水平有所下降但无统计学意义(P>0.05);B组患者IL-6水平有所下降,但无统计学意义(P>0.05),IL-10水平无明显变化.结论 IL-6可能作为判断新辅助化疗有效性的新的参考指标.

Research of changes of IL-6, IL.10 level before and after neoadjuvant chemotherapy in patients withadvanced gastric cancer and its clinical significance

Objective To observing the differences of IL-6, IL-10 level before and after neoadjuvant chemotherapy in patients with advanced gastric cancer, and search for a new reference for the effectiveness of neoadjuvant chemotherapy. Methods Detecting the level of IL-6, IL-10 before and after neoadjuvant chemotherapy in 51 patients with advanced gastric cancer,analyzing the effectiveness of neoadjuvant chemotherapy with the change of IL-6, IL-10. Patients were divided into group A （ effective group： CR ＋ PR）, group B （ ineffective group ： SD ＋ PD） according to the effectiveness of neoadjuvant chemotherapy. And then detecting the expression of IL-6 in gastric cancer tissues by immunohistochemical methods before and after neoadjuvant chemotherapy. Results In group A, the level of LL-6 decreased significantly（P 〈 0. 05 ） , IL-10 levels decreased but not statistically significant（ P 〉 0. 05 ） ;fn group B, IL-6 levels decreased but not statistically significant （ P 〉 0. 05 ）, IL-10 did not change significantly. Conclusions IL-6 may be used as a new reference for the effectiveness of neoadjuvant chemotherapy.